MAJOR PAPERS:

• The Wall Street Journal reported that the focus of reports of four deaths and 350 allergic reactions to Baxter International Inc's (NYSE: BAX) generic version of the blood thinner drug Heparin, and the ingredients supplied by a Chinese manufacturer, also includes Wisconsin-based Scientific Protein Laboratories, a co-owner of the Chinese manufacturing plant, and majority owned by American Capital Strategies Ltd (NASDAQ: ACAS), a Maryland buyout firm.
• Citigroup Incorporated (NYSE: C) has suspended investors at its CSO Partners hedge fund from withdrawing their money after they attempted to pull more than 30% of the fund's nearly $500M in assets, the Wall Street Journal reported.
• AT&T Inc (NYSE: T) is seeking more revenue from India as it tries to expand its consumer mobile phone operations outside the U.S, the Financial Times reported.

• According to the New York Times, the FDA broke its own rules by approving for sale Baxter International's Heparin without first inspecting a Chinese plant where the drug's key ingredient is made.

Wall Street's equity market offers a modest plate this week, with three IPOs and four Secondaries on the docket.

Those deals tentatively scheduled to price include:

IPOs:

Tuesday

• Aldabra 2 Acquisition (ALL.U), a 30M-share IPO for this business finance company. Lazard is the lead manager. Filing price: $10.00
• Sterlite Industries (SLT), a 125M-share IPO for this India-based metals company. Merrill Lynch, Morgan Stanley and Citigroup are the lead managers. Filing price: $13.85.

Thursday

• Care Investment Trust (CRE), an 18.75M-share IPO for this business finance company. Credit Suisse and Merrill Lynch are the lead managers. Filing range: $15.00-$17.00.